Publicacions en col·laboració amb investigadors/es de David Geffen School of Medicine at UCLA (4)

2022

  1. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 8, Núm. 1, pp. 31-38

2021

  1. Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease

    Clinical Cardiology, Vol. 44, Núm. 10, pp. 1457-1466

2019

  1. Updated Cost-effectiveness Analysis of Evolocumab in Patients with Very High-risk Atherosclerotic Cardiovascular Disease

    JAMA Cardiology

2016

  1. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

    Clinical Cardiology, Vol. 39, Núm. 6, pp. 313-320